Lineage Cell Therapeutics Inc (LCTX) - Total Assets
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) holds total assets worth $89.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lineage Cell Therapeutics Inc - Total Assets Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Lineage Cell Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Lineage Cell Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lineage Cell Therapeutics Inc's total assets of $89.64 Million consist of 45.0% current assets and 55.0% non-current assets. Review Lineage Cell Therapeutics Inc (LCTX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.4% |
| Accounts Receivable | $638.00K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $46.54 Million | 41.1% |
| Goodwill | $10.67 Million | 9.4% |
Asset Composition Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LCTX live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lineage Cell Therapeutics Inc's current assets represent 45.0% of total assets in 2024, a decrease from 100.0% in 1991.
- Cash Position: Cash and equivalents constituted 40.4% of total assets in 2024, down from 100.0% in 1991.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 1991.
- Asset Diversification: The largest asset category is intangible assets at 41.1% of total assets.
Lineage Cell Therapeutics Inc Competitors by Total Assets
Key competitors of Lineage Cell Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Lineage Cell Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.50 | 2.48 | 5.66 |
| Quick Ratio | 4.50 | 2.48 | 5.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $32.88 Million | $20.54 Million | $36.23 Million |
Lineage Cell Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Lineage Cell Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.45 |
| Latest Market Cap to Assets Ratio | 2.64 |
| Asset Growth Rate (YoY) | 12.1% |
| Total Assets | $113.22 Million |
| Market Capitalization | $299.43 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lineage Cell Therapeutics Inc's assets at a significant premium (2.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Lineage Cell Therapeutics Inc's assets grew by 12.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual total assets of Lineage Cell Therapeutics Inc from 1991 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $113.22 Million | +12.08% |
| 2023-12-31 | $101.02 Million | -18.31% |
| 2022-12-31 | $123.66 Million | -29.15% |
| 2021-12-31 | $174.54 Million | +61.69% |
| 2020-12-31 | $107.95 Million | -13.97% |
| 2019-12-31 | $125.48 Million | +23.43% |
| 2018-12-31 | $101.66 Million | -41.32% |
| 2017-12-31 | $173.24 Million | +21.51% |
| 2016-12-31 | $142.57 Million | +50.61% |
| 2015-12-31 | $94.66 Million | +26.38% |
| 2014-12-31 | $74.90 Million | +29.74% |
| 2013-12-31 | $57.73 Million | +94.06% |
| 2012-12-31 | $29.75 Million | -35.09% |
| 2011-12-31 | $45.83 Million | -13.97% |
| 2010-12-31 | $53.27 Million | +296.58% |
| 2009-12-31 | $13.43 Million | +1197.31% |
| 2008-12-31 | $1.04 Million | +491.35% |
| 2007-12-31 | $175.10K | -73.08% |
| 2006-12-31 | $650.51K | -66.79% |
| 2005-12-31 | $1.96 Million | +28.73% |
| 2004-12-31 | $1.52 Million | +42.00% |
| 2003-12-31 | $1.07 Million | -28.38% |
| 2002-12-31 | $1.50 Million | -22.94% |
| 2001-12-31 | $1.94 Million | +15.73% |
| 2000-12-31 | $1.68 Million | -70.46% |
| 1999-12-31 | $5.68 Million | +102.81% |
| 1998-12-31 | $2.80 Million | -66.27% |
| 1997-12-31 | $8.30 Million | +176.67% |
| 1996-12-31 | $3.00 Million | 0.00% |
| 1995-12-31 | $3.00 Million | -16.67% |
| 1994-12-31 | $3.60 Million | -38.98% |
| 1993-12-31 | $5.90 Million | +68.57% |
| 1992-12-31 | $3.50 Million | -27.08% |
| 1991-12-31 | $4.80 Million | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more